Fred Rasmussen
About
In The Last Decade
Fred Rasmussen
12 papers receiving 217 citations
Peers
Comparison fields: 5 of 65
- Oncology 111
- Molecular Biology 99
- Cancer Research 56
- Immunology and Allergy 48
- Radiology, Nuclear Medicine and Imaging 26
Countries citing papers authored by Fred Rasmussen
This map shows the geographic impact of Fred Rasmussen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Rasmussen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Rasmussen more than expected).
Fields of papers citing papers by Fred Rasmussen
This network shows the impact of papers produced by Fred Rasmussen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Rasmussen. The network helps show where Fred Rasmussen may publish in the future.
Co-authorship network of co-authors of Fred Rasmussen
This figure shows the co-authorship network connecting the top 25 collaborators of Fred Rasmussen. A scholar is included among the top collaborators of Fred Rasmussen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Rasmussen. Fred Rasmussen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 7 | |
| 2 | 3 | |
| 3 | 11 | |
| 4 | 8 | |
| 5 | 27 | |
| 6 | 88 | |
| 7 | 20 | |
| 8 | 49 | |
| 9 | Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma. | 6 |
| 10 | The Scandinavian Prostatic Cancer Group. | 2 |
| 11 | [Treatment of metastasizing renal adenocarcinoma with specific plasma transfusion. A controlled trial of the effects on metastases and survival time]. | 0 |
| 12 | Prostatic carcinoma treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan). | 2 |
| 13 | [The stability of iodophors]. | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.